Sangamo's Fabry gene therapy clears early clinical test, firing starting gun on preparations for phase 3

Sangamo Therapeutics has posted clinical data on a therapy it hopes will shake up the Fabry disease market. The gene therapy showed encouraging safety and efficacy signs in the small study, prompting Sangamo to start preparations for a phase 3 clinical trial.